Objective-Drugs that activate peroxisome proliferator-activated receptor (PPAR) ␥ improve glucose sensitivity and lower blood pressure, whereas dominant-negative mutations in PPAR␥ cause severe insulin resistance and hypertension. We hypothesize that these PPAR␥ mutants regulate target genes opposite to those of ligand-mediated activation, and we tested this hypothesis on a genomewide scale. Methods and Results-We integrated gene expression data in aorta specimens from mice treated with the PPAR␥ ligand rosiglitazone with data from mice containing a globally expressed knockin of the PPAR␥ P465L dominant-negative mutation. We also integrated our data with publicly available data sets containing the following: (1) gene expression profiles in many human tissues, (2) PPAR␥ target genes in 3T3-L1 adipocytes, and (3) experimentally validated PPAR␥ binding sites throughout the genome. Many classic PPAR␥ target genes were induced by rosiglitazone and repressed by dominant-negative PPAR␥. A similar pattern was observed for about 90% of the gene sets regulated by both rosiglitazone and dominant-negative PPAR␥. Genes exhibiting this pattern of contrasting regulation were significantly enriched for nearby PPAR␥ binding sites. Conclusion-These results provide convincing evidence that the PPAR␥ P465L mutation causes transcriptional effects that are opposite to those mediated by PPAR␥ ligand, thus validating mice carrying the mutation as a model of PPAR␥ interference. (Arterioscler Thromb Vasc Biol. 2010;30:518-525.)
P eroxisome proliferator-activated receptor (PPAR) ␥, a ligand-activated nuclear hormone receptor, plays a key role in the regulation of cellular lipid metabolism. 1 Thiazolidinedione medications that activate PPAR␥ have been prescribed to patients with documented success in improving glucose tolerance, improving insulin sensitivity, and lowering blood pressure. 2 In contrast, mutant forms of PPAR␥ that interfere with the PPAR␥ signaling pathway have been described in patients with high blood pressure and insulin resistance. 3 As a transcription factor, the physiological actions of PPAR␥ are attributable to alterations in the cell's gene expression profile, involving changes in the transcription of many target genes. For example, PPAR␥ plays a key role in the coordinated regulatory changes in many genes required for adipogenesis. 4 Genomewide analysis suggests that more than 5000 binding sites for PPAR␥ in chromatin are induced during adipogenesis. 5, 6 In addition, we have reported that ligand-mediated activation of PPAR␥ in blood vessel alters the expression of hundreds of genes. 7 It is not entirely clear how PPAR␥ mediates these largescale changes in gene transcription. One model of PPAR␥ action involves binding of PPAR␥ to specific DNA sequences, referred to as PPAR response elements (PPREs). 8 In the absence of ligand, PPAR␥, bound to the PPREs, recruits corepressors and inhibits gene expression. On ligand binding, either endogenous or pharmacological, there is a conformational change in PPAR␥, which leads to dismissal of the corepressors, recruitment of coactivators, and activation of the target gene. Recent genomewide chromatin immunoprecipitation studies 5,6 support the PPRE-dependent mechanism of gene regulation in 3T3-L1 adipocytes. In addition, it has been reported that PPAR␥ and other nuclear hormone receptors can decrease the expression of target genes in a DNA-binding independent, but ligand-dependent, mechanism called transrepression. 9 This mechanism appears to be important in PPAR␥mediated repression of proinflammatory genes.
Two rare, but naturally occurring, mutations in the ligandbinding domain of PPAR␥, causing severe insulin resistance and hypertension in humans, have been documented. 3 Molecular evidence demonstrates that these mutations possess dominant-negative (DN) activity and are able to compete against wild-type PPAR␥ for PPRE binding and to recruit corepressors, but are resistant to the conformational changes needed to dismiss the corepressors in the presence of ligand. 10, 11 Thus, DN PPAR␥ may regulate target genes in a direction opposite to ligand-induced activation.
To determine if PPAR␥-mediated regulation of target genes fits the expected pattern, we examined aortic RNA, using microarray analysis, from C57BL/6J mice in which PPAR␥ was activated by treatment with a pharmacological ligand, rosiglitazone (RZ), and from mice in which a globally expressed knockin of the PPAR␥ P465L DN mutation (G-DN) was used to interfere with the PPAR␥ signaling pathway. 12 
Methods

Experimental Procedures
The care and use of mice met the standard set forth by the National Institutes of Health, and all procedures were approved by the University Animal Care and Use Committee at the University of Iowa, Iowa City. Adult male mice (aged 5-7 months) were used for all experiments. G-DN experimental mice were generated by breeding inbred 129/SvEv heterozygous P465L knockin mice with C57BL/6J mice, to produce control and heterozygous P465L mice on an F1 genetic background that is isogenic except for the mutation at the PPAR␥ locus. 12 In these mice, the P465L mutation was knocked in to the mouse PPAR␥ gene using standard gene-targeting methods. More important, these mice contain one copy each of the wild-type and mutant PPAR␥ genes, both under the control of the endogenous PPAR␥ promoter and expressed in the same tissues. PPAR␥ was activated in C57BL/6J mice (Jackson Laboratories, Bar Harbor, Maine) by the administration of RZ for either 2 or 14 days at a dose of 3 or 10 mg/kg per day via a custom-made diet (Teklad, Madison, Wis). Control littermates were fed standard mouse chow. Mice were killed by carbon dioxide asphyxiation, and the thoracic aorta was quickly removed and frozen. Tissues were homogenized using a reagent (Tri-Reagent; Molecular Research Center, Cincinnati, Ohio), and the RNA was isolated as described by the manufacturer. The quality of the RNA was confirmed using a bioanalyzer (Agilent 2100 Bioanalyzer; Agilent Technologies, Santa Clara, Calif).
Gene Expression Profiling
For the microarray hybridizations, 3 separate biological replicates from each experimental group were used. Each biological replicate was a separate RNA pool derived from 8 to 9 different mouse thoracic aortas. The thoracic aorta was chosen for study based on previous data showing minimal dysfunction in this vessel in the G-DN mice. 13 Therefore, the gene expression difference can be attributed to PPAR␥ mutation and not vascular dysfunction. All the microarray procedures were conducted at the University of Iowa DNA Core Facility using standard protocols (Affymetrix, Santa Clara, Calif). Total RNA (approximately 3 g) was used as input to a one-step amplification procedure to generate biotin-labeled RNA fragments for hybridization to the array (GeneChip Mouse Genome 430 2.0 array; Affymetrix). Data from the microarray studies are publicly available at the Gene Expression Omnibus at the National Center for Biotechnology Information (array platform, GPL1261; series accession, GSE8949), as first described by Beyer et al 13 and reanalyzed herein.
Computational Analysis
Microarray data were analyzed using R statistical software and packages from the Bioconductor project. 14 Raw microarray data (ie, the *.CEL files) were imported into R and normalized using robust multiarray average. 15 The quality of the array hybridizations was confirmed by using the array quality control functions in Bioconductor. 16 One hybridization (RZ, 10 mg/kg per day, 14 days) failed quality control and was excluded from subsequent analysis. The differential expression of genes between groups and their corresponding genetically matched or vehicle-treated controls was determined using the linear models for microarray analysis (limma) package. 17 The adjusted probability value representing statistical significance was determined by analysis of the control probes (Affymetrix), as described by Smyth. 18 Determination of whether expression of a set of genes, as a group, was statistically changed was accomplished using the JAVA-based command line version of the Gene Set Enrichment Analysis tool (GSEA; available at: http://www.broad.mit.edu/gsea/). 19 For GSEA, the number of gene-set permutations was set at 1000 and PϽ0.05 was considered statistically significant. Statistical tests of term enrichment (modified Fisher exact test) were performed using the Database for Annotation, Visualization, and Integrated Discovery (DAVID; available at: http://david.abcc.ncifcrf.gov/) available at the National Institutes of Health. Additional methods and the algorithms used in the computational search for PPREs can be found in the Supplemental Methods, available online at http://atvb.ahajournals.org.
Real-Time Quantitative Polymerase Chain Reaction
Real-time quantitative polymerase chain reaction was performed using TaqMan Gene Expression Assays (Applied Biosystems, Foster City, Calif), as described in the Supplemental Methods.
Results
Genes Activated by RZ Are Repressed by DN PPAR␥
We first examined the expression of 37 PPAR␥ target genes (Supplemental Table I , available at http://atvb.ahajournals.org). These genes have been experimentally verified to be direct targets of PPAR␥ (Supplemental Methods). The expression of the classic PPAR␥ target fatty acid binding protein 4, also known as aP2, was significantly increased 2-fold by RZ in the aorta, and was decreased nearly 40% in mice containing the DN PPAR␥ (Supplemental Table II ). The set of PPAR␥ targets, as a group, was significantly increased by RZ (GSEA, PϽ0.001 in all 4 groups) and repressed by DN PPAR␥ (GSEA, Pϭ0.003). For the 71 probe sets representing these PPAR␥ targets, an inverse relationship was evident between the gene expression changes induced by PPAR␥ activation and interference ( Figure  1A and Supplemental Figure I ). There is a strong positive correlation (rϾ0.9) for comparisons between different RZ treatment groups, whereas there is a negative correlation (rϽϪ0.6) between the RZ and DN PPAR␥ group (Supplemental Figure I) .
We used GSEA to analyze the data (obtained from a publicly available repository; ArrayExpress ID, E-GEOD-1458; Gene Expression Omnibus Accession, GSE1458) from a control set of genes activated by RZ in 3T3-L1-differentiated adipocytes. The RZ-responsive genes identified in this study included known targets and genes without an association with PPAR␥. Probe sets considered "absent" (MAS 5.0; Affymetrix) were removed, and the data were sorted based on the level of induction by RZ. We then generated gene sets that were more stringent (only the 25 most induced genes) or less stringent (the top 150 induced genes). We also generated 4 additional gene sets of intermediate stringency (top 50, 75, 100, or 125 upregulated genes) and a set of 50 randomly selected genes. The set of genes induced by RZ in 3T3-L1 cells were then examined in aorta and were, as a set, increased (GSEA, PϽ0.05) after RZ treatment and decreased (GSEA, PϽ0.05) by DN PPAR␥ ( Supplemental Table III ). On the contrary, there was no enrichment for the randomly selected genes in any of our experimental groups.
GSEA was used to examine expression patterns from 2457 functional categories from Gene Ontology and the UniProt knowledgebase. There were 56 gene sets consistently upregulated and 100 gene sets downregulated by RZ (ie, different at a GSEA of PϽ0.05 in all 4 RZ treatment groups). Of the upregulated sets, 49 were either significantly repressed (GSEA, PϽ0.05) or showed a tendency to be repressed by DN PPAR␥ ( Supplemental Table IV ). Among them, gene sets were involved in cellular metabolism and ion transport. Of the 100 gene sets showing decreased expression by RZ, 25 were significantly upregulated (GSEA, PϽ0.05) in the G-DN mice, and included genes involved in the inflammatory response, consistent with the known anti-inflammatory actions of PPAR␥ (Supplemental Table IV ).
Identification of PPAR␥-Induced Target Genes
To generate a prioritized list of PPAR␥ targets (both direct and secondary), we integrated probe set level analyses from each of the experimental groups, combining the data from RZ-treated and G-DN data sets. The resulting set of genes is more likely to consist of genuine PPAR␥ targets and less likely to include genes whose expression changes were RZ specific but unrelated to PPAR␥. There were a similar number of genes upregulated (nϭ322) and downregulated (nϭ323) in the mice containing DN PPAR␥. In contrast, more genes were downregulated (between 195 and 1020 depending on dose and duration) than upregulated (between 186 and 315 depending on dose and duration) after RZtreatment, particularly in the mice receiving the higher dose (10 mg/kg per day). In total, 1679 unique genes were significantly regulated by RZ in at least 1 of the treatment groups. To increase specificity, we queried the data sets for genes that were regulated in at least two of the RZ groups and were oppositely regulated by DN. Twenty-eight RZ-induced genes involved in metabolism, lipid binding, and the peroxisome passed these criteria (Table 1) . 13 There is a strong positive correlation (rϾ0.9) between the RZ-treated groups (data not shown) and a negative correlation (rϽϪ0.8) between the RZ and DN PPAR␥ groups ( Figure 1B) . We validated the pattern of RZ-induced and DN-repressed expression of 4 of the highest ranked genes by quantitative polymerase chain reaction ( Figure 2 ).
Retinol-binding protein 7 (Rbp7), which shares homology with fatty acid binding protein 4, exhibited one of the most robust changes. To further examine the relationship between PPAR␥ and Rbp7, we compared their expression across a diverse range of human tissues using a publicly available microarray data set (available at: http://www.affymetrix.com/ support/technical/sample_data/exon_array_data.affx). Interestingly, the levels of expression of both fatty acid binding protein 4 ( Figure 1C , rϭ0.72) and Rbp7 ( Figure 1D , rϭ0.92) were highly correlated with the level of expression of PPAR␥.
There was a smaller group of genes significantly induced by RZ that exhibited either no change or a paradoxical increase by DN PPAR␥ ( Figure 3A , Supplemental Table V, and Supplemental  Table VII ). For example, heat shock proteins were enriched in this group (DAVID, Pϭ7.7ϫ10 Ϫ5 , Supplemental Figure II ).
Identification of Genes Repressed by PPAR␥
Unlike transcriptional induction by PPAR␥, ligand-bound PPAR␥ has been shown to decrease expression of target genes by blocking the action of other transcription factors by transrepression. This mechanism plays a role in PPAR␥-mediated repression of inflammatory cytokines; however, it is not known if the P465L mutation in PPAR␥ impairs its transrepression function and results in the upregulation of repressed genes. Among genes downregulated by RZ, 22 were also significantly upregulated in the G-DN mice ( Table 2) . As previously stated, we validated the expression pattern of Cyp2f2 by quantitative polymerase chain reaction ( Figure 2 ). The mouseNET database (available at: http://mousenet.princeton.edu/) combines experimental, genetic, and genomic data from a variety of public resources. We queried this database for genes from this set for evidence of linkage to inflammatory or nuclear factor B Table I ) relative to the appropriate control group for mice receiving daily rosiglitazone (RZ) (3 mg/kg for 14 days) compared with globally expressed knockin of the PPAR␥ P465L dominant-negative mutation (G-DN) mice. B, Scatterplot of fold changes in the expression of PPAR␥ target genes displaying the most expected expression pattern (Table 1) relative to the appropriate control group for mice receiving daily RZ (3 mg/kg for 14 days) compared with G-DN mice. Similar results were seen for the other RZ treatments groups (data not shown). C and D, Scatterplots of expression values across a diverse range of human tissues for PPAR␥, Rbp7, and fatty acid-binding protein 4. Values were obtained from a publicly available microarray data set provided by Affymetrix (available at: http://www.affymetrix.com/ support/technical/sample_data/exon_array_data.affx). The Pearson coefficient (R) was used as the metric for correlation. The identifier after the gene symbol is the probe set identifier (Affymetrix).
pathways. Linkage was found between LIMA1, a cytoskeletonassociated protein, and the nuclear factor B essential modulator protein (IKBKG or NEMO). Linkage was also found between four genes (LIMD2, CCR1, IL2RG, and IKZF1) and inflammatory-or immune-related signaling. FAM120b, also known as CCPG, was not found in the mouseNET database, but was recently reported to be a coactivator for PPAR␥ and to promote adipogenesis in a PPAR␥-dependent manner. 20 Interestingly, more genes that were downregulated by RZ exhibited a paradoxical pattern of downregulation in G-DN mice, suggesting that PPAR␥ carrying the DN mutation may retain an ability to repress transcription via transrepression (Supplemental Figure III , Supplemental Table VI, and Supplemental Table VII ).
List of Genes Altered Specifically by DN PPAR␥
Next, we determined if there were clusters of genes whose expression was altered by DN, but not by RZ. A total of 150 and 92 probe sets displayed DN-specific upregulation and downregulation, respectively. In this set of RZ-unresponsive genes, there was enrichment for genes involved in the regulation of transcription (Pϭ0.03) and oxidoreductase activity (Pϭ0.003) (Supplemental Table VIII ). The nuclear receptor NR2F2, also known as COUP-TFII, was one of the transcriptional regulators showing DN-specific activation. COUP-TFII has been reported to be able to bind to the PPRE upstream of the PEPCK (PCK1) gene, a known PPAR␥ target gene, and to negatively regulate its expression. 21 Therefore, some of the effects of DN PPAR␥ may be mediated by its effects on other transcriptional regulators.
Search for PPAR␥ Response Elements
The conventional model of PPAR␥-mediated gene activation requires binding to a PPRE; thus, RZ-induced genes should be enriched for nearby PPREs. Approximately 60% of the differentially expressed genes were associated with at least one computationally identified upstream PPRE. However, this did not represent an enrichment compared with a random set of genes, and the patterns of gene expression were similar regardless of the presence or absence of an upstream PPRE-like sequence (Supplemental Figure IV) . Therefore, we used a publicly available data set mapping the location of PPREs in 3T3-L1 adipocytes on the basis of function (chromatin immunoprecipitation and microarray hybridization [ChIP-chip]), not computational prediction. 5 Independent ChIP assays using quantitative polymerase chain reaction and custom microarrays demonstrated that the false discovery rate for this ChIP-chip experiment was low (3%-4%). To merge data sets, we limited our analysis to those genes that were consistently expressed in both aorta and 3T3-L1 adipocytes (3T3-L1 expression data; National Center for Biotechnology Information Gene Expression Omnibus Accession, GSE14004 and GSE8682). The set of genes activated by RZ was significantly enriched (PϽ0.01 by the Fisher exact test) for PPREs compared with either the set of genes downregulated by RZ or the set of all genes expressed both in aorta and 3T3-L1 adipocytes ( Table 3 ). The enrichment was particularly robust for those genes activated at multiple times or doses of RZ. There was also an enrichment in PPREs in genes that exhibited the pattern of opposite regulation (increased to RZ and decreased to DN) than those that exhibit a similar pattern of increased expression in response to RZ and DN ( Figure 3B ). Finally, we examined our prioritized sets of candidate PPAR␥ target genes. All 7 genes induced by RZ and repressed by DN and coexpressed in 3T3-L1 adipocytes were associated with a functionally validated PPRE (Table 3) . Alternatively, only 1 gene repressed by RZ and induced by DN was associated with a PPRE (Table 3 ).
Discussion
We examined global gene expression changes in the aorta in response to RZ and in gene-targeted mice containing a DN isoform of PPAR␥. Integrated analyses of results from these models suggest that the pathways regulated by PPAR␥ in the aorta are diverse and are most often regulated in the contrasting direction by the DN PPAR␥. The main findings of the study are as follow: (1) known validated PPAR␥ target genes are regulated in the aorta as they are in adipocytes; (2) known PPAR␥ target genes exhibit the expected opposite pattern of expression in response to PPAR␥ ligand and DN PPAR␥; (3) the changes in expression caused by PPAR␥ ligand and DN-PPAR␥ can be used to generate a prioritized list of target genes (in particular, genes induced by PPAR␥); (4) the expression of some PPAR␥ targets closely parallels the expression of PPAR␥ in tissues; (5) genes induced by RZ and repressed by DN-PPAR␥ are often associated with functionally validated PPAR␥ binding sites; and (6) the identification of PPAR␥ binding sites from one tissue can be used to potentially predict PPAR␥ target genes in another, as long as the genes are co-expressed in both tissues. Because of the commonality of PPAR␥ targets and associated PPAR␥ binding sites among cell types, PPAR␥ likely serves similarly conserved functions across diverse cells. In addition, the fact that the pattern of gene expression in response to DN-PPAR␥ was generally opposite to the response to PPAR␥ ligand suggests that models using DN-PPAR␥ accurately reflect interference with PPAR␥ signaling.
Transcriptional Induction and Repression by PPAR␥
Based on our analysis of a publicly available data set, we determined that many of the genes regulated by PPAR␥ in mouse aorta, particularly metabolism-related genes, are regulated by PPAR␥ in a similar manner as in a nonvascular cell type (ie, adipocytes). Therefore, it is tempting to speculate that at least part of the physiological actions of PPAR␥ in the vasculature may be secondary to a PPAR␥-mediated change in the cellular metabolic phenotype. For example, the activation of PPAR␥ in monocyte-derived dendritic cells was reported to be associated with the upregulation of genes involved in lipid metabolism and a reduction in lipid content, changes that might influence the immune response in these cells. 22 Whether PPAR␥ plays additional roles, such as providing antioxidant and anti-inflammatory defenses that are unique to the vasculature, remains to be determined. Although the most studied mechanism of ligand-mediated transactivation by PPAR␥ involves the PPRE, other indirect means may account for a significant fraction of the response to PPAR␥ (ie, the many genes downregulated by RZ). In fact, a much smaller percentage of the genes repressed by RZ had functionally validated PPRE sequences than those induced by RZ (Table 3 ). This suggests that the decrease in expression of non-PPRE-containing genes in response to ligand might be due to transrepression, a process requiring PPAR␥ ligand but not PPRE binding. Transrepression prevents the transcriptional induction caused by another transcription factor. For example, lipopolysaccharide-induced transcription of inducible nitric oxide synthase by nuclear factor B in macrophages is prevented by ligand-activated PPAR␥ via a PPRE-independent mechanism. 9 The prevalence of PPAR␥-mediated transrepression in the vasculature and the impact of DN PPAR␥ on this response are not known. If PPAR␥ transrepression is impaired by DN, it might explain the cluster of genes that are downregulated by RZ and upregulated by DN PPAR␥. More difficult to explain are the gene clusters whose expression changes in the same direction during both PPAR␥ activation and interference. This could potentially be interpreted as retention of the transrepression activity of DN PPAR␥. To our knowledge, there have been no studies examining the transrepression potential of DN mutants of PPAR␥.
PPAR␥ and the Vasculature
An association between PPAR␥, lipid metabolism, and vascular function is suggested by mice in which the PPAR␥ gene was deleted specifically from endothelial cells. 23 These mice have a normal blood pressure at baseline but become hypertensive after a high-fat diet. Control mice with intact PPAR␥ were resistant to the blood pressure-elevating effects of the high-fat diet, suggesting that PPAR␥ is protective. Similarly, we showed that mice specifically expressing DN PPAR␥ in endothelial cells exhibit high-fat diet-induced vascular dysfunction. 24 Because various lipid molecules can act as a ligand to activate PPAR␥, it has been suggested that PPAR␥ acts as a "fatty acid sensor." 25 Activated PPAR␥ then, via its actions on gene transcription, could reprogram the cellular gene expression profile to adapt to the new environmental inputs. It remains unclear which endogenous lipids act as true ligands to PPAR␥ in vivo.
In addition to the endothelium, we showed that vascular muscle PPAR␥ is crucial to the regulation of arterial pressure and vascular function. Targeting the DN P467L mutation in PPAR␥ to vascular muscle in transgenic mice resulted in severely impaired vasodilatation, augmented vasoconstriction, and moderate hypertension. 26 Based on our data, we were surprised by recent reports 27, 28 presenting contradictory data on blood pressure in mice lacking PPAR␥ in vascular muscle cells. Wang et al 27 reported increased arterial pressure, whereas Chang et al 28 reported hypotension, in similar models of smooth muscle PPAR␥ deficiency using the Cre-loxP system. The contradictory data may be attributable to differences in the SM22␣-cre models used by both groups, one being a transgenic 27 and the other being a knockin 28 model. Despite these differences, the data beg the questions of how vascular muscle-specific DN interference causes hypertension and how vascular muscle-specific ablation causes hypotension?
Does this mean that interference and deficiency are not equivalent? Perhaps this may be explained by the mechanism of gene induction by PPAR␥. In the absence of ligand, PPAR␥/ retinoid X receptor heterodimers can interact with a PPRE and with recruit corepressors, thus repressing transcription. The corepressors are dismissed and replaced by coactivators when PPAR␥ ligand is present (ie, ligand-mediated transactivation). Evidence suggests that DN PPAR␥ can outcompete wild-type PPAR␥ for the PPRE binding as the result of a reduction in receptor recycling rate, thus preserving or extending the state of transcriptional repression. 10 Alternatively, PPAR␥ deficiency may reduce or remove the repressive state by eliminating the recruitment of corepressors, thus causing some level of transcriptional activation through other elements of the transcriptional machinery. Indeed, Duan and colleagues 29 suggested the concept that the phenotype of gene deficiency may mimic agonist-mediated induction as the result of gene suppression that both agonist and genetic deficiency are capable of relieving. Support for this differential model of DN interference versus PPAR␥ deficiency comes from the following: (1) our data showing reproducible repression of genes induced by RZ, in particular those with functionally validated PPREs; and (2) data reporting activation of the PPAR␥ target gene ␤2-adrenergic receptor expression by RZ, genetic deficiency, or short hairpin RNA-mediated ablation of PPAR␥. 28 Consistent with this, PPAR␥-mediated repression of ␤2-adrenergic receptor required DNA binding because it was abolished by mutations in the DNA binding domain of PPAR␥. Consequently, although DN PPAR␥ appears to act as a bonafide inhibitor of PPAR␥-mediated induction, PPAR␥ deficiency may actually provide a gain of function, thus emulating some of the phenotypes associated with thiazolidinedione treatment (ie, lowered arterial pressure).
Perspectives
The many differentially expressed genes in most microarray experiments has made prioritizing the gene list an important task, so that experimental efforts can be directed toward the most attractive genes or pathways. For studies involving pharmacological agents, off-target and dose-or time-dependent effects can result in changes in gene expression that hinder the identification of the primary target genes. By integrating results from pharmacological studies and gene-targeted mouse models in the present study, we have generated a list of approximately 30 target genes that demonstrate significant responses consistent with the conventional model of PPAR␥ action. Further bioinformatic analysis of freely available data sets revealed some of these to be coexpressed in 3T3-L1 cells and to contain PPREs. One of these (eg, RBP7) must be promoted on the list because it was one of the most robustly induced by RZ and repressed by DN, and its expression correlated well with PPAR␥ in many tissues. RBP7 expression is induced several days after the start of differentiation of 3T3-L1 cells, and its promoter contains several PPRE sequences that were shown to bind PPAR␥ by electrophoretic mobility-shift assay and ChIP, and were functional in transfection assays. 5, 30 Studies of RBP7-deficient mice revealed a role in lipid and whole body energy metabolism. 30 RBP7 becomes an even more attractive candidate when one considers that Caprioli et al 31 showed that it is expressed in microvascular endothelial cells. These two observations (ie, an involvement in lipid and energy metabolism and its expression in endothelium) are particularly interesting in light of our data showing high-fat diet-induced vascular dysfunction in mice specifically expressing DN PPAR␥ in the endothelium. 24 Consequently, examining the role of RBP7 in the blood vessel wall is a necessary next step.
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